Bipolar Depression Market Expected to Witness Accelerated Expansion During the Forecast Period (2026-2036) Amid Advancements in Psychiatric Therapies | DelveInsight [Yahoo! Finance]
Xenon Pharmaceuticals Inc. - Common Shares (XENE)
Last xenon pharmaceuticals inc. - common shares earnings: 11/5 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.xenon-pharma.com
Company Research
Source: Yahoo! Finance
such as Azetukalner (Xenon Pharmaceuticals), Elunetirom (ABX-002) (Autobahn Therapeutics), ABBV-932 and Icalcaprant (ABBV-1354) (AbbVie), ALTO-100 (Alto Neuroscience), NRX-101 (NRx Pharmaceuticals), LB-102 (LB Pharmaceuticals), and others and healthcare spending across the 7MM, reports DelveInsight. LAS VEGAS March 11, 2026 /PRNewswire/ -- Recently published Bipolar Depression Market Insights report includes a comprehensive understanding of current treatment practices, bipolar depression emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. DelveInsight Logo Bipolar Depression Market Summary The total bipolar depression treatment market size is expected to grow positively by 2036 in the leading markets. The United States accounted for the largest bipolar depression treatment market size in 20
Show less
Read more
Impact Snapshot
Event Time:
XENE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XENE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XENE alerts
High impacting Xenon Pharmaceuticals Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
XENE
News
- Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares [Yahoo! Finance]Yahoo! Finance
- Assessing Xenon Pharmaceuticals (XENE) Valuation After A Sharp Recent Share Price Surge [Yahoo! Finance]Yahoo! Finance
- Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional SharesGlobeNewswire
- Xenon Pharmaceuticals prices upsized $650M public offering at $57/share [Seeking Alpha]Seeking Alpha
- Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public OfferingGlobeNewswire
XENE
Earnings
- 2/26/26 - Miss
XENE
Sec Filings
- 3/13/26 - Form 4
- 3/13/26 - Form 4
- 3/13/26 - Form 4
- XENE's page on the SEC website